ES2151054T3 - Farmaco para el tratamiento de la artritis reumatoide. - Google Patents

Farmaco para el tratamiento de la artritis reumatoide.

Info

Publication number
ES2151054T3
ES2151054T3 ES95913319T ES95913319T ES2151054T3 ES 2151054 T3 ES2151054 T3 ES 2151054T3 ES 95913319 T ES95913319 T ES 95913319T ES 95913319 T ES95913319 T ES 95913319T ES 2151054 T3 ES2151054 T3 ES 2151054T3
Authority
ES
Spain
Prior art keywords
rheumatoid arthritis
drug
treatment
remedy
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95913319T
Other languages
English (en)
Inventor
Tadashi Nishida
Sachiko Miyake
Hideo Yagita
Ko Okumura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanebo Ltd
Original Assignee
Kanebo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanebo Ltd filed Critical Kanebo Ltd
Application granted granted Critical
Publication of ES2151054T3 publication Critical patent/ES2151054T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

REMEDIO PARA LA ARTRITIS REUMATOIDE QUE CONTIENE COMO INGREDIENTE ACTIVO UN ANTICUERPO MONOCLONAL QUE RECONOCE DE FORMA ESPECIFICA UNA ZONA EXTRACELULAR DEL VLA-2, PREFERIBLEMENTE UNO QUE CONTENGA UN ANTICUERPO MONOCLONAL QUE RECONOZCA ESPECIFICAMENTE UNA ZONA EXTRACELULAR DE LA CADENA {AL} DEL VLA-2 HUMANO. EL REMEDIO PUEDE SUPRIMIR LA INFLAMACION DEBIDA A LA ARTRITIS CAUSADA POR LA ARTRITIS REUMATOIDE Y ES ESCASAMENTE TOXICO, POR LO QUE SE CONVIERTE EN EFICAZ PARA EL TRATAMIENTO DE LA ARTRITIS REUMATOIDE.
ES95913319T 1994-04-26 1995-03-22 Farmaco para el tratamiento de la artritis reumatoide. Expired - Lifetime ES2151054T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8825194 1994-04-26

Publications (1)

Publication Number Publication Date
ES2151054T3 true ES2151054T3 (es) 2000-12-16

Family

ID=13937651

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95913319T Expired - Lifetime ES2151054T3 (es) 1994-04-26 1995-03-22 Farmaco para el tratamiento de la artritis reumatoide.

Country Status (9)

Country Link
US (1) US5855888A (es)
EP (1) EP0759302B1 (es)
AT (1) ATE195428T1 (es)
DE (1) DE69518415T2 (es)
DK (1) DK0759302T3 (es)
ES (1) ES2151054T3 (es)
GR (1) GR3034200T3 (es)
PT (1) PT759302E (es)
WO (1) WO1995028961A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020030A1 (en) * 1998-10-07 2000-04-13 Karolinska Innovations Ab Anti-inflammatory alpha2, beta1 integrin-related substances or antibodies
NZ541431A (en) * 1999-04-22 2008-01-31 Biogen Idec Inc Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
BR0011250A (pt) 1999-06-01 2002-03-05 Biogen Inc Anticorpo monoclonal de bloqueio a vla-1 e seu uso para o tratamento de distúrbios inflamatórios
US6146639A (en) * 1999-07-26 2000-11-14 Merich Nick Arthritis, muscle pain, and dry skin remedy
AU2002258778C1 (en) * 2001-04-13 2008-12-04 Biogen Ma Inc. Antibodies to VLA-1
US20030013107A1 (en) * 2001-06-07 2003-01-16 Rigel Pharmaceuticals, Incorporated Alpha 2 integrin: modulators of lymphocyte activation
EP3023497A1 (en) * 2005-11-18 2016-05-25 Glenmark Pharmaceuticals S.A. Anti-alpha2 integrin antibodies and their uses
PT2034830E (pt) * 2006-05-25 2014-10-14 Biogen Idec Inc Anticorpos anti-vla-1 para o tratamento de acidentes vasculares cerebrais
US20080267978A1 (en) * 2006-08-28 2008-10-30 Mary Zutter Anti-angiogenic targets for cancer therapy
EP3623381A1 (en) * 2011-05-19 2020-03-18 The Regents Of The University Of Michigan Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
AU2013221635B2 (en) 2012-02-16 2017-12-07 Santarus, Inc. Anti-VLA1 (CD49a) antibody pharmaceutical compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330506A3 (en) * 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
DK162890D0 (da) * 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid
EP1266965B1 (en) * 1991-07-25 2006-05-24 Biogen Idec Inc. Recombinant antibodies for human therapy

Also Published As

Publication number Publication date
DE69518415D1 (de) 2000-09-21
EP0759302A1 (en) 1997-02-26
DE69518415T2 (de) 2001-01-25
EP0759302A4 (en) 1997-11-19
GR3034200T3 (en) 2000-11-30
PT759302E (pt) 2001-01-31
EP0759302B1 (en) 2000-08-16
WO1995028961A1 (fr) 1995-11-02
US5855888A (en) 1999-01-05
DK0759302T3 (da) 2000-11-13
ATE195428T1 (de) 2000-09-15

Similar Documents

Publication Publication Date Title
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
ES2151054T3 (es) Farmaco para el tratamiento de la artritis reumatoide.
DE69634609D1 (de) Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu-opioidanagonisten und eines kappa - 2- opioidanagonisten
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
DK0605501T5 (da) Anvendelse af præsynaptisk neurotoksin til behandling af cerebel parese
ITMI910584A1 (it) Composizione farmaceutica idrofila contenente ketoprofene sale di lisina per uso topico.
MD1591B2 (ro) Derivaţi ai peptidelor cu activitate terapeutică
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
KR930702000A (ko) 노년기 치매, 식용항진, 편두통, 또는 식용불량의 치료를 위한 파로세틴의 사용
DK0603301T3 (da) Farmaceutisk præparat indeholdende et urikosurikon og en excitatorisk-aminosyre-antagonist
ZA828048B (en) Novel anti-cancer drugs for the treatment of leukaemias t constituted by the chain a of ricin and a specific monoclonal antibody
BR9807796A (pt) Processos para tratar da incontinência urinária, de vertigem e da doença do movimento, e, composição farmacêutica.
DE60116302D1 (de) Behandlung von seborrhoischer dermatitis
FR2700472B1 (fr) Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
ES2181702T3 (es) Derivados de melatonina para su uso en el tratamiento de enfermedad es del sueño.
DK0656773T3 (da) Anvendelse af radikalfangere som immunmodulerende agenser i kosmetiske og dermatologiske tilberedninger.
MX9303023A (es) Composicion farmaceutica para tratar desordenes gastricos.
SE9404331L (sv) Förfarande för sträckning av en materialbana vid framställning av vätskeabsorberande alster och anordning för materialbanans sträckning
KR940703666A (ko) 발기 부전증 치료에 효능있는 약제(a potent drug for treatment of erectile dysfunction)
ES2049711T3 (es) Uso de bucilamina para la fabricacion de un medicamento para el tratamiento de cistinuria.
DE69230644T2 (de) Verwendung von protease nexin-i als mittel gegen entzündungen
RU94032792A (ru) Применение 5нтiа - антагонистов для прекращения использования табака
EA199600048A3 (ru) N,n-диэтил-8,8-дипропил-2-азаспиро[4,5]декан-2-пропанамин дималеат, фармацевтическая композиция на его основе и способ индуцирования иммуномодуляции
DE59305285D1 (de) Transdermales therapeutisches system mit pentylentetrazol als wirkstoff
KR950007852A (ko) 우라실을 유효성분으로 함유하는 관절염 치료제

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 759302

Country of ref document: ES